UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report(Date of earliest event reported) September 1, 2003
TEKRON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-29493 51-0395658
State or other jurisdiction Commission File IRS Employer
of incorporation) Number Identification No.
530 S. Federal Highway Deerfield Beech, FL 33441
(Address of principal executive offices) (Zip/Postal Code)
Registrant's telephone number: 519-661-0609
N/A
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
Dr. James Insell has been appointed as CEO and Chief Scientic Officer. His
qualifications are outlined in a recent press release.
Mr. Marvin Winick has been appointed as CFO of the Company. He is a
Canadian accountant with several years of public company experience.
The Company has also appointed the following legal firms as counsel.
In Canada - Carlyle Peterson, Gordon Peterson and Phil King
In the United States - Lawrence S. Hartman
ITEM 7. EXHIBITS
Press release of September 8, 2003 incorporated by reference, a copy of
which is attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: September 9, 2003 TEKRON, INC.
By: s/s LUIGI BRUN
------------------------------
Luigi Brun
President
Press Release Source: Tekron, Inc.
Tekron, Inc. Announces the Appointment of Dr. James P. Insell as CEO, and
Chief Scientific Officer Monday September 8, 1:18 pm ET
FORT LAUDERDALE, Fla., September 8, 2003 (PRIMEZONE) -- Tekron, Inc. (OTC
BB:TKRN.OB - News) announces that Luigi Brun, Chairman and President is pleased
to appoint Dr. James Insell as CEO and Chief Scientific Officer for the
Corporation.
Dr. Insell, 55, has served as President and CEO of Microbe Corporation a
publicly traded environmental biotechnology for twelve years as well as
President of J.P. Insell & Associates, scientists and engineers for the past
five years. He consulted for the investment banking community, biopharma venture
capitalists, and a group of high net-worth investors in Europe providing
scientific audits, engineering assessments and corporate due diligence. Dr.
Insell's career began as a professor of microbiology at UWO in Canada.
Subsequently, he founded a biotech company based on his discovery of microbial
ontogenetic evolution. For the next eight years he developed and patented
designer bacteria for biopesticides and toxic waste degradation. For several
years, he worked in the biotech community in San Diego and at the University of
California, San Diego as consulting associate director of science and
engineering. Currently, due to his knowledge of and experience with anthrax, he
has provided lectures and protocols for counter-bioterrorism to large automotive
corporations and financial institutions.
Luigi Brun, Chairman and President of Tekron, said "I am extremely pleased
that Dr. Insell has demonstrated his confidence by joining and heading up the
team at Tekron. I look forward to his scientific contribution and the technology
he has developed over the past two decades."
Dr. Insell stated, "I am excited about joining Tekron at this very exciting
and opportunistic point in the Company's history. I am confident that we can
move our technology forward rapidly in the best interests of the shareholders."
About Dr. Insell
Dr. Insell received his B.Sc. in engineering physics from the University of
Waterloo in 1972. His scientific training broadened as he took positions at The
Hospital for Sick Children, Sunnybrook Hospital, Toronto, Ontario and the
University of Toronto, Department of Surgery studying the ultrastructure of
hyperacute rejection, human fetal lung development and extracorporal renal
viability in the laboratories of Dr. Martin Barkin, Dr. Cohen and Dr. G. A
Taylor. He pursued his electron microscopic interests studying the genetics,
ultrastructure and physiology of predacious fungi receiving his M. Sc. in
microbiology in 1975 from the University of Waterloo. His elucidation of the
novel biophysics of these fascinating microorganisms was featured by the
prestigious journal New Scientist. He continued his studies of the molecular
genetics and biochemistry of pathogenic sporulating bacilli, Bacillus
thuringiensis and Bacillus anthracis in the laboratories of Dr. Phil Fitz-James,
Department of Bacteriology and Immunology at the University of Western Ontario
and subsequently earned his Ph.D in bacteriology and immunology from the School
of Medicine in 1982. His studies led to an understanding of the origin of the
pathogenicity of sporulating bacilli and their evolution. He undertook his
postdoctoral training studying the ultrastructure, physiology and biochemistry
of psychrophilic and mesophilic pathogenic fungi. Dr. Insell took a faculty
position in the Department of Life Sciences, pursuing his research interests in
molecular evolution. In1984, Dr. Insell took his discovery of microbial
ontogenetic evolution and founded a biotechnology company commercializing this
finding. For the next eight years, he developed and patented bacteria that
degrade toxic waste as well as developed novel strains of the insecticidal
bacteria Bacillus thuringiensis and Bacillus laterosporus and the renown human
pathogen Bacillus anthracis (anthrax). Dr. Insell took the first biotech company
public in Canada. Dr. Insell was featured in the Canadian Business Magazine as
well as being nominated for the highly prestigious Ernest Manning leading
Canadian scientist award in 1986. From 1996 to 1998, Dr. Insell resided in San
Diego and became actively involved in it's biotech community, culminating in
becoming a consulting biotechnology associate director in engineering and
science at the University of California, San Diego. Before returning to Canada,
Dr. Insell liaised with state and federal legislators, sat on the Biocom
employment taskforce, working with many of the over three hundred and fifty
biotechnology companies in San Diego and contributed to the biotechnology
curriculum development at UCSD. He originated and developed several new courses
at UCSD in design of clinical trials, FDA approval procedures, GLP and GMP. Dr.
Insell has authored over ten peered reviewed scientific publications, two
patents and over fifty scientific reports and engineering assessments. For the
past five years, Dr Insell has been president of J.P Insell & Associates,
consulting scientists and engineers, undertaking scientific audits and
engineering assessments for investment banking and biopharma venture
capitalists. As an environmental engineer as well as a bacteriologist, Dr.
Insell has designed and implemented numerous novel treatment systems and site
remediations and has been involved in the development of a treatment for herpes,
atherosclerosis and a cure for psoriasis. Most recently, Dr. Insell has been
retained by large automotive corporations and financial institutions to provide
consulting and laboratory services for the identification and countermeasure
response to germ warfare agents and the response to other unidentified
bioharzardous materials (RUM). Dr. Insell has developed bioharzard response
protocols and designed an emergency responder biohazard kit (equipment) for RUM.
Dr Insell teaches these protocols to the medical staff and emergency response
personnel in the automotive industry. Dr. Insell lectures on anthrax, tularemia,
plague, botulinum, ricin, smallpox and other viral infections such as West Nile
virus, SARS, bovine spongiformy encephalitis (mad cows disease) and their
corporate response.
About Tekron:
Tekron Inc. is a holding company acquiring interests in high technology,
medical and environmental biotechnology companies. This information contains
certain forward-looking statements and information relating to the Company that
are based on the beliefs of the Company or management as well as assumptions
made by and information currently available to the Company or management. When
used in this document, the words "anticipate," "believe," "estimate," "expect"
and "intend" and similar expressions, as they relate to the Company or its
management, are intended to identify forward-looking statements. Such statements
reflect the current view of the Company regarding future events and are subject
to certain risks, uncertainties and assumptions, including the risks and
uncertainties noted. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated, expected or intended. In each instance, forward-looking information
should be considered in light of the accompanying meaningful cautionary
statements herein.
Contact:
Tekron, Inc.
Mr. Luigi Brun,
Tel: 519-661-0509
Fax: 519-667-0366
Email: luigibrun@tekron-inc.com
Or
Dr. James Insell
Tel: 519-433-4400
Fax: 519-432-0535
Email: jpinsell@execulink.com
Source: Tekron, Inc.
